US 12,258,567 B2
Artificial nucleic acid molecules
Thomas Schlake, Gundelfingen (DE); and Stefanie Grund, Stuttgart (DE)
Assigned to CureVac SE, Tübingen (DE)
Appl. No. 15/755,739
Filed by CureVac SE, Tübingen (DE)
PCT Filed Aug. 22, 2016, PCT No. PCT/EP2016/001417
§ 371(c)(1), (2) Date Feb. 27, 2018,
PCT Pub. No. WO2017/036580, PCT Pub. Date Mar. 9, 2017.
Claims priority of application No. PCT/EP2015/001755 (WO), filed on Aug. 28, 2015.
Prior Publication US 2018/0237786 A1, Aug. 23, 2018
Int. Cl. C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12N 15/67 (2006.01); A01K 67/00 (2006.01)
CPC C12N 15/67 (2013.01) 18 Claims
 
1. A purified RNA molecule comprising:
(a) at least one open reading frame (ORF);
(b) at least one 3′-untranslated region element (3′-UTR element), which is heterologous relative to the ORF, comprising a sequence at least 90% identical to the RNA sequence encoded by SEQ ID NO: 164; and,
(c) optionally, at least one 5′-untranslated region element (5′-UTR element).